Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD5335 + saruparib
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous (AZD5335), Oral (saruparib)
01
Overview
AZD5335 + saruparib is a combination therapy being investigated in clinical trials for advanced solid tumors, particularly ovarian cancer and lung adenocarcinoma. AZD5335 is a folate receptor \u03b1 (FR\u03b1)-targeted antibody-drug conjugate (ADC) designed to selectively deliver cytotoxic agents to cancer cells expressing FR\u03b1, sparing healthy tissue. Saruparib (also known as AZD5305) is an orally administered, next-generation, highly selective poly(ADP-ribose) polymerase 1 (PARP1) inhibitor that promotes cancer cell death by impairing DNA repair, with improved tolerability compared to earlier PARP inhibitors. The combination is intended to leverage targeted cytotoxicity from AZD5335 and synthetic lethality from PARP inhibition by saruparib, offering a potential synergistic anti-cancer effect[2][4][6].
- Other names
- saruparib
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)FOLR1 (FRα)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on AZD5335 + saruparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD5335 + saruparib.